Russell Investments Group Ltd. Purchases 355,915 Shares of OraSure Technologies, Inc. $OSUR

Key Points

• Russell Investments Group Ltd. has increased its stake in OraSure Technologies by 111.1%, acquiring a total of 676,334 shares valued at approximately $2.28 million.
• Several hedge funds have also raised their positions in OraSure Technologies, with institutional investors now owning 93.50% of the company's stock.
• OraSure Technologies' stock has recently seen a price increase of 4.7% and is currently trading around $3.14, with a market cap of $229.65 million.

Russell Investments Group Ltd. boosted its stake in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 111.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 676,334 shares of the medical instruments supplier's stock after purchasing an additional 355,915 shares during the period. Russell Investments Group Ltd. owned approximately 0.87% of OraSure Technologies worth $2,279,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in OSUR. Invesco Ltd. grew its position in OraSure Technologies by 3.4% in the 4th quarter. Invesco Ltd. now owns 127,526 shares of the medical instruments supplier's stock worth $460,000 after purchasing an additional 4,240 shares during the period. Legal & General Group Plc grew its position in OraSure Technologies by 32.3% in the 4th quarter. Legal & General Group Plc now owns 23,626 shares of the medical instruments supplier's stock worth $85,000 after purchasing an additional 5,770 shares during the period. Raymond James Financial Inc. bought a new stake in OraSure Technologies in the 4th quarter worth approximately $37,000. XTX Topco Ltd bought a new stake in OraSure Technologies in the 4th quarter worth approximately $177,000. Finally, Tower Research Capital LLC TRC grew its position in OraSure Technologies by 202.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 5,234 shares during the period. Institutional investors own 93.50% of the company's stock.

OraSure Technologies Price Performance

Shares of NASDAQ OSUR traded up $0.02 during midday trading on Friday, reaching $3.31. 747,291 shares of the stock traded hands, compared to its average volume of 623,367. The stock has a market capitalization of $242.09 million, a PE ratio of -4.94 and a beta of 0.44. OraSure Technologies, Inc. has a one year low of $2.36 and a one year high of $4.61. The company's 50 day moving average is $3.07 and its 200 day moving average is $3.09.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of OraSure Technologies from a "sell" rating to a "hold" rating in a research report on Saturday, May 17th. Evercore ISI reissued an "in-line" rating and set a $3.00 price objective on shares of OraSure Technologies in a research report on Monday, May 19th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $3.00.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.